Psychiatric Times
Vol 43, Issue 1
Vol 42, Issue 12
Vol 42, Issue 11
Vol 42, Issue 10
Vol 42, Issue 9
Vol 42, Issue 8
Vol 42, Issue 7
Vol 42, Issue 6
Vol 42, Issue 5
Vol 42, Issue 4
Vol 42, Issue 3
Vol 42, Issue 2
Vol 42, Issue 1
Vol 41, Issue 12
Vol 41, Issue 11
Vol 41, Issue 10
Vol 41, Issue 9
Vol 41, Issue 8
Vol 41, Issue 7
Vol 41, Issue 6
Vol 41, Issue 5 Addiction Digital Supplement
Vol 41, Issue 5
Vol 41, Issue 4
Vol 41, Issue 3
Vol 41, Issue 2
Vol 41, Issue 1
Vol 40, Issue 12
Vol 40, Issue 11
Vol 40, Issue 10
Vol 40, Issue 9
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Accepts Investigational New Drug Application for COMP360 for PTSD
2
New Phase 3 Clinical Vocal Biomarker Data on Brilaroxazine to Treat Negative Symptoms in Schizophrenia
3
Zervimesine May Slow Progression of Dementia With Lewy Bodies, Phase 2 Results Show
4
FDA Grants Breakthrough Therapy Designation to Alixorexton for the Treatment of Narcolepsy Type 1
5